Paper Details

  1. Home
  2. Paper Details

Osimertinib for the treatment of patients with <i>EGFR</i> mutation-positive non-small cell lung cancer.

Author: AlsharediM, BukamurH, ElhamdaniA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

EGFR mutations are common in non-small cell lung cancer (NSCLC), particularly in Asian patients. EGFR tyrosine kinase inhibitors (TKIs) are effective, but resistance often develops. Osimertinib is a third-generation TKI that can overcome resistance, particularly in patients with the T790M mutation.
Paper Details　
Original Abstract of the Article :
Epidermal growth factor receptor (EGFR) mutations, mostly seen in exon 19 or exon 21, are present in roughly 50% of patients with advanced non-small cell lung cancer (NSCLC) of Asian ethnicity compared with 12% in Caucasians. EGFR-mutated NSCLC patients have an increased sensitivity to EGFR tyrosine...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1358/dot.2018.54.6.2817668

データ提供：米国国立医学図書館（NLM）

Osimertinib: A New Weapon in the Fight Against EGFR-Mutated Lung Cancer

This review provides a comprehensive look at [osimertinib], a [third-generation tyrosine kinase inhibitor] for the treatment of [EGFR mutation-positive non-small cell lung cancer (NSCLC)]. The authors explore the significance of [EGFR mutations] in lung cancer, highlighting the importance of [molecular-guided precision therapy].

The paper details [osimertinib]'s [pharmacology], [pharmacokinetics], [safety], [side effects], and [clinical utility], providing a valuable resource for healthcare professionals. They emphasize the importance of [osimertinib] in addressing [acquired resistance] to previous [EGFR-TKIs].

Precision Therapy: Tailoring Treatment to Individual Patients

The development of [osimertinib] represents a significant advancement in [precision medicine]. By targeting specific [molecular mutations], this therapy provides a more effective and targeted approach to treating [EGFR-mutated NSCLC]. This personalized approach allows for better outcomes and fewer side effects for patients.

Hope for Patients with Lung Cancer

This research offers hope for patients with [EGFR-mutated NSCLC]. The development of [osimertinib] provides a new weapon in the fight against this challenging disease, allowing for improved [survival rates] and [quality of life].

Dr.Camel's Conclusion

This review provides an essential overview of [osimertinib], a groundbreaking treatment for [EGFR-mutated NSCLC]. The development of this targeted therapy represents a testament to the progress in [molecular medicine]. It's a reminder that even in the face of complex diseases like lung cancer, research can provide innovative solutions and improve the lives of countless individuals.

Date :
  1. Date Completed 2018-09-04
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

29998228

DOI: Digital Object Identifier

10.1358/dot.2018.54.6.2817668

Related Literature

Article Analysis
・Side Effects of osimertinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.